{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"","title":"1.24 - Next Steps for Psychedelic-Assisted Therapies in Australia","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61ce5d7240b3c90013933ba8/1679031091398-7a5e0551a310da91aa88ad1512039fdf.jpeg?height=200","description":"
In this podcast, we discuss what the next steps are, following the TGA's decision to change the classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists.
The mission of Mind Medicine in light of the rescheduling of psilocybin and MDMA for medical use in Australia effective July 1st, 2023.
The podcast will shift focus towards a more in-depth analysis of newly published research articles on psychedelics, as well as previous research
Mind Medicine Australia is a non-profit organization dedicated to increasing medical access and awareness of psychedelic-assisted therapies.
Psychedelics are chemical compounds that temporarily alter brain function resulting in an \"altered state of consciousness.\"
Mind Medicine Australia aims to provide better treatment options for patients suffering from mental illness, with a focus on developing clinical implementation frameworks and therapist training protocols.
Starting July 1, 2023, authorized prescribers will be able to prescribe psilocybin and MDMA for patients with treatment-resistant depression and post-traumatic stress disorder.
Mind Medicine Australia is arranging for these medicines to be supplied through licensed pharmacists holding Schedule 8 permits.
Only specialized psychiatrists who meet certain qualifications will be able to prescribe psilocybin and MDMA.
Australia is the first nation in the world to reschedule these medicines for medical purposes.
Mind Medicine Australia has trained 240 medical professionals through its Certificate in Psychedelic-Assisted Therapies (CPAT) since 2021, and will shortly be launching dates for 2023 intakes.